Contact Us
Drug Search Results
More Filters [+]

Zotarolimus

Alternative Names: zotarolimus
Latest Update: 2024-10-28
Latest Update Note: News Article

Product Description

Mechanisms of Action: Immunosuppressive

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Percutaneous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: Australia | Colombia

Approved Indications: None

Known Adverse Events: None

Company: Medtronic
Company Location: DUBLIN L2 2
Company CEO: Geoffrey S. Martha
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Zotarolimus

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 4: Myocardial Ischemia|Coronary Artery Disease|Coronary Disease|ST Elevation Myocardial Infarction|Myocardial Infarction

Phase 3: Coronary Artery Disease|Myocardial Ischemia|Arteriosclerosis

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
ONYSOVER

N/A

Recruiting

Coronary Artery Disease|Myocardial Ischemia

2025-12-31

ZEVS-HBR

N/A

Recruiting

Coronary Artery Disease

2024-02-28

CNUH-2017-319

N/A

Completed

Myocardial Ischemia|Coronary Artery Disease

2021-03-18

MDT16058RES004

N/A

Active, not recruiting

Arteriosclerosis|Coronary Artery Disease|Myocardial Ischemia

2021-02-24

Recent News Events

Date

Type

Title

10/28/2024

News Article

 Elixir Medical's DynamX Bioadaptor Demonstrates Significant Improvement Over Contemporary Drug-Eluting Stent in Patients with Acute Coronary Syndrome and Complex Lesion Subsets After Six Months

08/13/2024

News Article

 Elixir Medical to Present Late-Breaking One-Year Primary Outcomes from the 2,400 Patient INFINITY-SWEDEHEART Clinical Trial at ESC Congress 2024

05/07/2024

PubMed

 Final 5-year report of BIONYX comparing the thin-composite wire-strut zotarolimus-eluting stent versus ultrathin-strut sirolimus-eluting stent.

04/30/2024

News Article

 Elixir Medical To Announce Data from Three Platforms Designed to Transform Cardiovascular Disease Treatment at EuroPCR 2024, Including Two Late-Breakers

02/27/2024

PubMed

 Testing a Cloud-Based Model for Active Surveillance of Medical Devices with Analyses of Coronary Stent Safety Using the Data Extraction and Longitudinal Trend Analysis (DELTA) System.

02/01/2024

PubMed

 Seven-year follow-up of endovascular treatment of iatrogenic brachioradial artery injury complicating percutaneous coronary intervention: a case report.

10/04/2023

News Article

 Elixir Medical Completes Submission of DynamX Coronary Bioadaptor System to Japan's PMDA Agency for Regulatory Approval

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions